Screening of gestational diabetes mellitus in early pregnancy by oral glucose tolerance test and glycosylated fibronectin: Study protocol for an international, prospective, multicentre cohort trial

BMJ Open

Volumn 6, Issue 10, 2016, Pages

  Huhn, E A ^a   Fischer, T ^b   Gobl C S ^c   Todesco Bernasconi, M ^d   Kreft, M ^e   Kunze, M ^f   Schoetzau, A ^a   Dolzlmuller E ^b   Eppel, W ^c   Husslein, P ^c   Ochsenbein Koelble, N ^e   Zimmermann, R ^e   Baz E ^f   Prompeler H ^f   Bruder, E ^a   Hahn, S ^g   Hoesli, I ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^d CANTONAL HOSPITAL AARAU   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF BASEL   (Switzerland)

Author keywords

diagnosis; Gestational diabetes mellitus; glycosylated fibronectin; oral glucose tolerance test; pregnancy; screening

Indexed keywords

ADIPONECTIN; CHORIONIC GONADOTROPIN; FIBRONECTIN; GLUCOSE; GLYCOSYLATED FIBRONECTIN; HEMOGLOBIN A1C; INSULIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PREGNANCY ASSOCIATED PROTEIN; UNCLASSIFIED DRUG; VITAMIN D; FIBRONECTIN, GLYCOSYLATED;

APGAR SCORE; ARTICLE; BIRTH INJURY; CHROMOSOME ABERRATION; CLINICAL TRIAL; COHORT ANALYSIS; CONGENITAL MALFORMATION; DEPRESSION; ECHOGRAPHY; FEMALE; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; HISTOLOGY; HUMAN; HYDRAMNIOS; HYPOGLYCEMIA; INTENSIVE CARE; JAUNDICE; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MULTICENTER STUDY; ORAL GLUCOSE TOLERANCE TEST; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE LABOR; PROSPECTIVE STUDY; QUESTIONNAIRE; RESPIRATORY DISTRESS SYNDROME; SCREENING; SHOULDER DYSTOCIA; STRESS; ADULT; ANALYSIS; AUSTRIA; BLOOD; EARLY DIAGNOSIS; GERMANY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; MASS SCREENING; MATERNAL CHILD HEALTH CARE; METABOLISM; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PROCEDURES; RISK FACTOR; SWITZERLAND;

ADULT; AUSTRIA; BLOOD GLUCOSE; DIABETES, GESTATIONAL; EARLY DIAGNOSIS; FEMALE; FIBRONECTINS; GERMANY; GLUCOSE TOLERANCE TEST; HUMANS; MASS SCREENING; MATERNAL-CHILD HEALTH CENTERS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SWITZERLAND;

EID: 84991736348     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-012115     Document Type: Article

References (52)

1. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care 2015;38 Suppl:S8-16.
2. Aziz NL, Abdelwahab S, Moussa M, et al. Maternal fructosamine and glycosylated haemoglobin in the prediction of gestational glucose intolerance. Clin Exp Obstet Gynecol 1992;19:235-41.
3. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477-86.
4. Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
5. Casey BM, Lucas MJ, Mcintire DD, et al. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol 1997;90:869-73.
6. Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009;373:1773-9.
7. Osgood ND, Dyck RF, Grassmann WK. The inter-and intragenerational impact of gestational diabetes on the epidemic of type 2 diabetes. Am J Public Health 2011;101:173-9.
8. Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-82.
9. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for Good Clinical Practice. J Postgrad Med 2001;47(1):45-50.
10. Rasanen J, Quinn MJ, Laurie A, et al. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol 2015;212:82. e1-9.
11. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. WHO, 2006. http://www. who. int/diabetes/publications/diagnosis-diabetes2006/en
12. Lehmann R, Troendle A, Brändle M. [New insights into diagnosis and management of gestational diabetes mellitus: recommendations of the Swiss Society for Endocrinology and Diabetes]. Ther Umsch 2009;66:695-706.
13. Kleinwechter H, Schäfer-Graf U, Bührer C, et al. Gestational diabetes mellitus (GDM) diagnosis, therapy and follow-up care: practice Guideline of the German Diabetes Association (DDG) and the German Association for Gynaecology and Obstetrics (DGGG). Exp Clin Endocrinol Diabetes 2014;122:395-405.
14. Kautzky-Willer A, Bancher-Todesca D, Pollak A, et al. [Gestational diabetes mellitus]. Wien Klin Wochenschr 2012;124(Suppl 2):58-65.
15. Rasanen JP, Snyder CK, Rao PV, et al. Glycosylated fibronectin as a first-trimester biomarker for prediction of gestational diabetes. Obstet Gynecol 2013;122:586-94.
16. Corrado F, D'Anna R, Cannata ML, et al. Correspondence between first-trimester fasting glycaemia, oral glucose tolerance test in gestational diabetes diagnosis. Diabetes Metab 2012;38:458-61.
17. Huhn EA, Massaro N, Streckeisen S, et al. Fourfold increase in prevalence of gestational diabetes mellitus after adoption of the new International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. J Perinat Med 2016. doi:10. 1515/jpm-2016-0099 [Epub ahead of print 10 AUg 2016].
18. Ryser Ruëtschi J, Jornayvaz FR, Rivest R, et al. Fasting glycaemia to simplify screening for gestational diabetes. BJOG 2016. http://dx. doi. org/10. 1111/1471-0528. 13857 [Epub ahead of print].
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
20. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: prediction, inference and data mining. Springer Verlag, 2009.
21. Nanda S, Savvidou M, Syngelaki A, et al. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 2011;31:135-41.
22. Iliodromiti S, Sassarini J, Kelsey TW, et al. Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis. Diabetologia 2016;59:692-9.
23. Fasshauer M, Blüher M, Stumvoll M. Adipokines in gestational diabetes. Lancet Diabetes Endocrinol 2014;2:488-99.
24. Yadav A, Kataria MA, Saini V, et al. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013;417:80-4.
25. Nagalla SR, Snyder CK, Michaels JE, et al. Maternal serum biomarkers for risk assessment in gestational diabetes. A potential universal screening test to predict GDM status. Indian J Endocrinol Metab 2015;19:155-9.
26. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
27. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
28. Norman AW, Frankel JB, Heldt AM, et al. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980;209:823-5.
29. Maestro B, Molero S, Bajo S, et al. Transcriptional activation of the human insulin receptor gene by 1, 25-dihydroxyvitamin D(3). Cell Biochem Funct 2002;20:227-32.
30. Takiishi T, Ding L, Baeke F, et al. Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. Diabetes 2014;63:2026-36.
31. Riachy R, Vandewalle B, Moerman E, et al. 1, 25-dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006;11: 151-9.
32. Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 2007;20:189-209.
33. Dressendörfer RA, Kirschbaum C, Rohde W, et al. Synthesis of a cortisol-biotin conjugate and evaluation as a tracer in an immunoassay for salivary cortisol measurement. J Steroid Biochem Mol Biol 1992;43:683-92.
34. Christ-Crain M, Fenske W. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol 2016;12:168-76.
35. Reinstadler SJ, Klug G, Feistritzer HJ, et al. Copeptin testing in acute myocardial infarction: ready for routine use? Dis Markers 2015;2015:614145.
36. Zhang R, Liu J, Zhang Y, et al. Association between circulating copeptin level and mortality risk in patients with intracerebral hemorrhage: a systemic review and meta-analysis. Mol Neurobiol 2016. doi:10. 1007/s12035-015-9626-z [Epub ahead of print]
37. Viasus D, Del Rio-Pertuz G, Simonetti AF, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect 2016;72:273-82.
38. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385-96.
39. Silveira ML, Whitcomb BW, Pekow P, et al. Perceived psychosocial stress and glucose intolerance among pregnant Hispanic women. Diabetes Metab 2014;40:466-75.
40. Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Res 1967;11:213-18.
41. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987;150:782-6.
42. Byrn M, Penckofer S. The relationship between gestational diabetes and antenatal depression. J Obstet Gynecol Neonatal Nurs 2015;44:246-55.
43. Ertel KA, Silveira M, Pekow P, et al. Prenatal depressive symptoms and abnormalities of glucose tolerance during pregnancy among Hispanic women. Arch Womens Ment Health 2014;17:65-72.
44. Desoye G, Gauster M, Wadsack C. Placental transport in pregnancy pathologies. Am J Clin Nutr 2011;94(Suppl):1896S-902S.
45. Jarmuzek P, Wielgos M, Bomba-Opon D. Placental pathologic changes in gestational diabetes mellitus. Neuro Endocrinol Lett 2015;36:101-5.
46. Bernischke K, Burton GJ, Baergen RN. Pathology of the Human Placenta. Vol Sixth, Springer-Verlag Berlin Heidelberg, 2012.
47. Riskin-Mashiah S, Younes G, Damti A, et al. First-trimester fasting hyperglycemia and adverse pregnancy outcomes. Diabetes Care 2009;32:1639-43.
48. Nielsen KK, de Courten M, Kapur A. The urgent need for universally applicable simple screening procedures and diagnostic criteria for gestational diabetes mellitus-lessons from projects funded by the World Diabetes Foundation. Glob Health Action 2012;5. doi:10. 3402/gha. v5i0. 17277
49. Werner EF, Pettker CM, Zuckerwise L, et al. Screening for gestational diabetes mellitus: are the criteria proposed by the international association of the diabetes and pregnancy study groups cost-effective? Diabetes Care 2012;35:529-35.
50. Marseille E, Lohse N, Jiwani A, et al. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern Fetal Neonatal Med 2013;26:802-10.
51. Mission JF, Ohno MS, Cheng YW, et al. Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis. Am J Obstet Gynecol 2012;207:326. e1-9.
52. Sanabria-Martínez G, Garciá-Hermoso A, Poyatos-León R, et al. Effectiveness of physical activity interventions on preventing gestational diabetes mellitus and excessive maternal weight gain: a meta-analysis. BJOG 2015;122:1167-74.